VANTAGE study of Vercise DBS system shows benefits for Parkinson's Disease - Boston Scientific

Patients with Parkinson's disease (PD) treated with the Boston Scientific Vercise Deep Brain Stimulation (DBS) System demonstrated a highly significant and consistent improvement in motor scores, according to the latest one-year data. VANTAGE is a prospective, multi-center trial evaluating the Vercise DBS System assessing patient outcomes in PD, including effectiveness, safety and health economic data. Forty patients with PD were treated with the Vercise DBS System at six European centers.

The VANTAGE study reported a 62 percent improvement in motor function at 12 months post implant, as assessed by the UPDRS III1 scale, when compared to baseline. This result is consistent with the six month interim data presented last year, demonstrating that patients benefitted from therapy over time. In addition, patients reduced medication usage by 58 percent at 12 months compared to their usage prior to the DBS procedure. Results of the follow-up were presented at the 18th International Congress of Parkinson's Disease and Movement Disorders.